Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

C.J. Ryan, M. Rosenthal, S. Ng, J. Alumkal, J. Picus, G. Gravis, K. Fizazi, F. Forget, J.P. Machiels, S. Srinivas, M. Zhu, R. Tang, K.S. Oliner, Y.Z. Jiang, E. Loh, S. Dubey, W.R. Gerritsen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)215-224
JournalClinical Cancer Research
Volume19
Issue number1
DOIs
Publication statusPublished - 2013

Cite this

Ryan, C.J. ; Rosenthal, M. ; Ng, S. ; Alumkal, J. ; Picus, J. ; Gravis, G. ; Fizazi, K. ; Forget, F. ; Machiels, J.P. ; Srinivas, S. ; Zhu, M. ; Tang, R. ; Oliner, K.S. ; Jiang, Y.Z. ; Loh, E. ; Dubey, S. ; Gerritsen, W.R. / Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. In: Clinical Cancer Research. 2013 ; Vol. 19, No. 1. pp. 215-224.
@article{6234b7d14d554b60853ce436d9f681cf,
title = "Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone",
author = "C.J. Ryan and M. Rosenthal and S. Ng and J. Alumkal and J. Picus and G. Gravis and K. Fizazi and F. Forget and J.P. Machiels and S. Srinivas and M. Zhu and R. Tang and K.S. Oliner and Y.Z. Jiang and E. Loh and S. Dubey and W.R. Gerritsen",
year = "2013",
doi = "10.1158/1078-0432.CCR-12-2605",
language = "Undefined/Unknown",
volume = "19",
pages = "215--224",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

Ryan, CJ, Rosenthal, M, Ng, S, Alumkal, J, Picus, J, Gravis, G, Fizazi, K, Forget, F, Machiels, JP, Srinivas, S, Zhu, M, Tang, R, Oliner, KS, Jiang, YZ, Loh, E, Dubey, S & Gerritsen, WR 2013, 'Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone' Clinical Cancer Research, vol. 19, no. 1, pp. 215-224. https://doi.org/10.1158/1078-0432.CCR-12-2605

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. / Ryan, C.J.; Rosenthal, M.; Ng, S.; Alumkal, J.; Picus, J.; Gravis, G.; Fizazi, K.; Forget, F.; Machiels, J.P.; Srinivas, S.; Zhu, M.; Tang, R.; Oliner, K.S.; Jiang, Y.Z.; Loh, E.; Dubey, S.; Gerritsen, W.R.

In: Clinical Cancer Research, Vol. 19, No. 1, 2013, p. 215-224.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

AU - Ryan, C.J.

AU - Rosenthal, M.

AU - Ng, S.

AU - Alumkal, J.

AU - Picus, J.

AU - Gravis, G.

AU - Fizazi, K.

AU - Forget, F.

AU - Machiels, J.P.

AU - Srinivas, S.

AU - Zhu, M.

AU - Tang, R.

AU - Oliner, K.S.

AU - Jiang, Y.Z.

AU - Loh, E.

AU - Dubey, S.

AU - Gerritsen, W.R.

PY - 2013

Y1 - 2013

U2 - 10.1158/1078-0432.CCR-12-2605

DO - 10.1158/1078-0432.CCR-12-2605

M3 - Article

VL - 19

SP - 215

EP - 224

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 1

ER -